Repurposing an atherosclerosis targeting peptide for tumor imaging

Cancer and atherosclerosis are chronic diseases that share common characteristics at both early and advanced stages and can arise from multiple factors. Both diseases are characterized by uncontrolled cell proliferation, inflammation, angiogenesis and apoptosis. Herein we investigated the ability of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luciana Kovacs, Ryan A. Davis, Tanushree Ganguly, Roger Chammas, Julie L. Sutcliffe
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Optical imaging Tumor Atherosclerosis Stroma Peptide Sulfo-Cy5 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/eaeab13a66ea471e81bc95943e857678
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eaeab13a66ea471e81bc95943e857678
record_format	dspace
spelling	oai:doaj.org-article:eaeab13a66ea471e81bc95943e8576782021-12-02T04:59:07ZRepurposing an atherosclerosis targeting peptide for tumor imaging0753-332210.1016/j.biopha.2021.112469https://doaj.org/article/eaeab13a66ea471e81bc95943e8576782022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221012555https://doaj.org/toc/0753-3322Cancer and atherosclerosis are chronic diseases that share common characteristics at both early and advanced stages and can arise from multiple factors. Both diseases are characterized by uncontrolled cell proliferation, inflammation, angiogenesis and apoptosis. Herein we investigated the ability of a peptide (CTHRSSVVC), that was previously reported to bind atherosclerotic lesions to home in the tumor microenvironment. The CTHRSSVVC peptide was synthesized on solid phase and N-terminally labeled with a sulfo-Cy5 dye. The specific binding to macrophage was evaluated in vitro with flow cytometry and immunofluorescence and in vivo for tumor targeting in BALB/c mice bearing a 4T1 tumor using optical imaging. The sulfo-Cy5-CTHRSSVVC peptide was synthesized in greater than 99% purity. No selective binding of the sulfo-Cy5-CTHRSSVVC peptide to macrophages in vitro was observed, however in vivo the sulfo-Cy5-CTHRSSVVC peptide accumulated in the 4T1 tumor, with a tumor-to-normal tissue ratio of 7.21 ± 1.44 at 2 h post injection. Ex vivo analysis of tumor tissue by confocal microscopy suggested that the sulfo-Cy5-CTHRSSVVC peptide had accumulated in the stroma of the tumor specifically, in regions of spindle shaped cells. In conclusion, although the target for the sulfo-Cy5-CTHRSSVVC peptide remains to be identified, the Cy5-CTHRSSVVC peptide warrants further investigation as a tumor imaging agent.Luciana KovacsRyan A. DavisTanushree GangulyRoger ChammasJulie L. SutcliffeElsevierarticleOptical imagingTumorAtherosclerosisStromaPeptideSulfo-Cy5Therapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112469- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Optical imaging Tumor Atherosclerosis Stroma Peptide Sulfo-Cy5 Therapeutics. Pharmacology RM1-950
spellingShingle	Optical imaging Tumor Atherosclerosis Stroma Peptide Sulfo-Cy5 Therapeutics. Pharmacology RM1-950 Luciana Kovacs Ryan A. Davis Tanushree Ganguly Roger Chammas Julie L. Sutcliffe Repurposing an atherosclerosis targeting peptide for tumor imaging
description	Cancer and atherosclerosis are chronic diseases that share common characteristics at both early and advanced stages and can arise from multiple factors. Both diseases are characterized by uncontrolled cell proliferation, inflammation, angiogenesis and apoptosis. Herein we investigated the ability of a peptide (CTHRSSVVC), that was previously reported to bind atherosclerotic lesions to home in the tumor microenvironment. The CTHRSSVVC peptide was synthesized on solid phase and N-terminally labeled with a sulfo-Cy5 dye. The specific binding to macrophage was evaluated in vitro with flow cytometry and immunofluorescence and in vivo for tumor targeting in BALB/c mice bearing a 4T1 tumor using optical imaging. The sulfo-Cy5-CTHRSSVVC peptide was synthesized in greater than 99% purity. No selective binding of the sulfo-Cy5-CTHRSSVVC peptide to macrophages in vitro was observed, however in vivo the sulfo-Cy5-CTHRSSVVC peptide accumulated in the 4T1 tumor, with a tumor-to-normal tissue ratio of 7.21 ± 1.44 at 2 h post injection. Ex vivo analysis of tumor tissue by confocal microscopy suggested that the sulfo-Cy5-CTHRSSVVC peptide had accumulated in the stroma of the tumor specifically, in regions of spindle shaped cells. In conclusion, although the target for the sulfo-Cy5-CTHRSSVVC peptide remains to be identified, the Cy5-CTHRSSVVC peptide warrants further investigation as a tumor imaging agent.
format	article
author	Luciana Kovacs Ryan A. Davis Tanushree Ganguly Roger Chammas Julie L. Sutcliffe
author_facet	Luciana Kovacs Ryan A. Davis Tanushree Ganguly Roger Chammas Julie L. Sutcliffe
author_sort	Luciana Kovacs
title	Repurposing an atherosclerosis targeting peptide for tumor imaging
title_short	Repurposing an atherosclerosis targeting peptide for tumor imaging
title_full	Repurposing an atherosclerosis targeting peptide for tumor imaging
title_fullStr	Repurposing an atherosclerosis targeting peptide for tumor imaging
title_full_unstemmed	Repurposing an atherosclerosis targeting peptide for tumor imaging
title_sort	repurposing an atherosclerosis targeting peptide for tumor imaging
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/eaeab13a66ea471e81bc95943e857678
work_keys_str_mv	AT lucianakovacs repurposinganatherosclerosistargetingpeptidefortumorimaging AT ryanadavis repurposinganatherosclerosistargetingpeptidefortumorimaging AT tanushreeganguly repurposinganatherosclerosistargetingpeptidefortumorimaging AT rogerchammas repurposinganatherosclerosistargetingpeptidefortumorimaging AT julielsutcliffe repurposinganatherosclerosistargetingpeptidefortumorimaging
_version_	1718400925068951552

Repurposing an atherosclerosis targeting peptide for tumor imaging

Ejemplares similares